Terminated PHASE2 INTERVENTIONAL 2-arm NCT01756924

Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection

Sponsor: Arrevus Inc.

Conditions Infected Spacers Prosthetic Joint Infections of Hip Prosthetic Joint Infections of Knee

Interventions CEM-102 IV or Oral standard of care antibiotics Rifampin

Updated 12 times since 2017 Last updated: Apr 15, 2019 Started: Dec 31, 2012 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This study has been terminated; alternative study designs are being considered. Fusidic acid remains available under an Expanded Access Protocol.

A PHASE2 clinical study on Infected Spacers and Prosthetic Joint Infections of Hip, this trial is terminated or withdrawn. The trial is conducted by Arrevus Inc. and has accumulated 12 data snapshots since 2012. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

12 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Apr 2022 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2021 — Apr 2022 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2

▶ Show 7 earlier versions

Nov 2020 — Jan 2021 [monthly]

Terminated PHASE2
May 2019 — Nov 2020 [monthly]

Terminated PHASE2
Jun 2018 — May 2019 [monthly]

Terminated PHASE2
May 2018 — Jun 2018 [monthly]

Terminated PHASE2
Aug 2017 — May 2018 [monthly]

Terminated PHASE2
Feb 2017 — Aug 2017 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Arrevus Inc.

Data source: Arrevus Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Boston, United States , Charleston, United States , Durham, United States , Houston, United States , Philadelphia, United States , Pittsburgh, United States , Sarasota, United States , Savannah, United States , Syracuse, United States and 1 more location